anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present disclosure provides a method of providing instructions for preparing and verifying the preparation of a medication that is to be administered to a patient using a drug delivery system based upon a medication order. The method includes receiving, at a system, an indication of the medication to be prepared for administration to the patient. The method further includes displaying, on a user interface of the system, a list of one or more items required for medication preparation, including medication, device, and label components. The method further includes scanning, at a scan-enabled client module of the system, a scannable code on each of the one or more items. The method further includes, for at least one item of the one or more items, displaying, on the user interface of the system, a set of one or more instructions specific to the at least one item of the one or more items. The method further includes, after assembling the one or more items required for medication preparation into an assembled unit, verifying one or more features of the assembled unit.
An initial safety evaluation will be performed in participants with relapsed AML. If atezolizumab in combination with Hu5F9-G4 is initially safe and tolerable in participants an additional cohort with R/R AML will be evaluated to further test the safety and anti-tumor activity. If dose-limiting toxicities (DLT) are observed in \>=33% of participants in this initial cohort, a dose de-escalation cohort will be enrolled. If less than 33% of enrolled and dosed participants in any given cohort experience a DLT, an expansion cohort of 15 participants will be enrolled at the highest tolerated dose for this combination. If a dose de-escalation cohort is needed, an expansion cohort will be enrolled at the lower tolerated dose for this combination.
BACKGROUND: Socioeconomic status (SES) is a driver of health disparities and chronic diseases. People with HIV (PWH) are at risk for chronic liver diseases. We evaluated the association between low SES and hepatic outcomes in PWH.
METHODS: We included PWH from a prospective cohort. SES was assessed by the Pampalon material and social deprivation index to classify the cohort into quintiles of deprivation. Multivariable linear regression was used to investigate associations of material and social deprivation with liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) as markers of hepatic fibrosis and steatosis, respectively. Incidence of outcomes was evaluated through survival analysis.
RESULTS: Among the 804 PWH included, 45% and 72% were living in areas of the highest material and social deprivation, respectively. Materially deprived PWH were more frequently female and of non-white ethnicity and had higher prevalence of metabolic comorbidities. After adjustments, material deprivation correlated with increased LSM (β = 1.86, 95% CI 0.53-3.17) but not with CAP (β = 6.47, 95% CI -5.55-18.49). Patients were observed for a median follow-up of 3.8 years. Incidence of liver-related events was higher in most materially deprived compared to most privileged PWH (hazard ratio 3.03, 95% CI 1.03-8.92), while there was no difference in extrahepatic outcomes or all-cause mortality. Social deprivation showed no association with either LSM or clinical outcomes.
CONCLUSIONS: Living in materially deprived neighbourhoods as a proxy for lower SES, is associated with LSM and liver-related events in PWH. Future strategies should explore mechanisms underlying these relationships and whether enhanced material security improves hepatic outcomes.
The efficacy of OLINVYK was established in two randomized, double-blind, placebo- and morphine-controlled studies of patients with moderate to severe acute pain following orthopedic surgery-bunionectomy or plastic surgery-abdominoplasty. In each study, pain intensity was measured using a patient-reported numeric rating scale (11-point numerical scale ranging from 0-10, where zero corresponds to no pain and 10 corresponds to worst pain imaginable).

In each study, patients were randomized to one of three OLINVYK treatment regimens, a placebo-control regimen, or a morphine-control regimen. Each blinded treatment regimen consisted of a loading dose, incremental doses delivered as needed via patient-controlled analgesia (PCA) device, and supplemental doses, beginning 1 hour after the initial dose, and hourly thereafter, as needed. The loading dose for all OLINVYK treatment regimens was 1.5 mg; demand doses were 0.1, 0.35 or 0.5 mg, according to the assigned treatment group; supplemental doses were 0.75 mg. The loading dose for the morphine treatment regimen was 4 mg; the demand dose was 1 mg; supplemental doses were 2 mg. The placebo-control regimen was volume-matched. A lockout interval of 6 minutes was used for all PCA regimens. For Studies 1 and 2, patients may have received rescue pain medication (pre-defined in the protocols as etodolac 200 mg every 6 hours, as needed) if the patient requested rescue pain medication and reported a Numeric Rating Scale score ≥4.
BACKGROUND: The benefit of oral anticoagulation in atrial fibrillation (AF) is well established for patients at elevated stroke risk, but less clear for those at intermediate risk. We investigated whether analysis of electrocardiogram (ECG) derived fibrillatory waves (F-waves) could help identify patients at risk for stroke and systemic embolism (SSE).
METHODS: The Finnish Cardioversion (FinCV) study included patients not on permanent anticoagulation therapy who underwent cardioversion for an acute AF episode. We identified 739 individuals with a valid ECG and complete follow-up data. The maximum amplitudes of the F-waves in leads II and V1 were manually measured from the pre-procedure ECG. Patients were categorized into fine and coarse F-wave groups. The optimal lead and amplitude threshold for grouping were found in an events per person-years analysis. SSE were identified from the patient medical records until either anticoagulation was prescribed, AF was deemed chronic, the patient had deceased, or the end of follow-up.
RESULTS: Overall 37 (5.0%) patients suffered SSE during the median follow-up time of 5.4 years (1.9-10.8). Measured from lead V1 the SSE rates per 100 person-years were 1.5 and 0.7 in fine and coarse F-wave groups, respectively. Fine F-waves were observed in 112 (15.2%). Baseline characteristics were similar between the groups. Fine F-wave predicted SSE in a competing risk analysis (SHR 2.34, 95%CI 1.12-4.87, p = .023). Analyses from lead II did not provide significant results.
CONCLUSION: Electrocardiographic F-wave amplitude may provide additional information on stroke risk in patients with paroxysmal AF and borderline indications or contraindications for anticoagulation.
The orally taken Ribavirin dropping pill contains Ribavirin 1-12 mg each and proper amount of matrix. The matrix may be one of polyglycol-6000, polyglycol-4000, polyoxyethylene monostearate, sodium stearate, etc. or their composition. The preparation process includes mixing Ribavirin and heated and smelted matrix, dropping the mixture at 50-120 deg.c into condensing agent to form dropping pill, eliminating condensing agent, inspection and packing. The condensing agent is one or several of dimethyl silicon oil, liquid paraffin, rape seed oil and tea seed oil. The Ribavirin dropping pill may be used in preventing and treating viral respiratory tract infection and other viral infection, and has the features of high efficiency and less side effect.
(see BOXED WARNING) Because of the risk of potentially fatal, acute fulminant liver failure, Tolcapone tablets should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies (see INDICATIONS and DOSAGE AND ADMINISTRATION sections).

Because of the risk of liver injury and because Tolcapone tablets, when it is effective, provides an observable symptomatic benefit, the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from Tolcapone tablets.

Tolcapone tablets therapy should not be initiated if the patient exhibits clinical evidence of liver disease or two SGPT/ALT or SGOT/AST values greater than the upper limit of normal. Patients with severe dyskinesia or dystonia should be treated with caution (see PRECAUTIONS: Rhabdomyolysis).

Patients who develop evidence of hepatocellular injury while on Tolcapone tablets and are withdrawn from the drug for any reason may be at increased risk for liver injury if Tolcapone tablets is reintroduced. Accordingly, such patients should not ordinarily be considered for retreatment.

In controlled Phase 3 trials, increases to more than 3 times the upper limit of normal in ALT or AST occurred in approximately 1% of patients at 100 mg tid and 3% of patients at 200 mg tid. Females were more likely than males to have an increase in liver enzymes (approximately 5% vs 2%). Approximately one third of patients with elevated enzymes had diarrhea. Increases to more than 8 times the upper limit of normal in liver enzymes occurred in 0.3% at 100 mg tid and 0.7% at 200 mg tid. Elevated enzymes led to discontinuation in 0.3% and 1.7% of patients treated with 100 mg tid and 200 mg tid, respectively. Elevations usually occurred within 6 weeks to 6 months of starting treatment. In about half the cases with elevated liver enzymes, enzyme levels returned to baseline values within 1 to 3 months while patients continued Tolcapone tablets treatment. When treatment was discontinued, enzymes generally declined within 2 to 3 weeks but in some cases took as long as 1 to 2 months to return to normal.

Monoamine oxidase (MAO) and COMT are the two major enzyme systems involved in the metabolism of catecholamines. It is theoretically possible, therefore, that the combination of Tolcapone tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. For this reason, patients should ordinarily not be treated concomitantly with Tolcapone tablets and a non-selective MAO inhibitor.

Tolcapone can be taken concomitantly with a selective MAO-B inhibitor (e.g., selegiline).
Speech perception requires the binding of spatiotemporally disjoint auditory-visual cues. The corresponding brain network-level information processing can be characterized by two complementary mechanisms: functional segregation which refers to the localization of processing in either isolated or distributed modules across the brain, and integration which pertains to cooperation among relevant functional modules. Here, we demonstrate using functional magnetic resonance imaging recordings that subjective perceptual experience of multisensory speech stimuli, real and illusory, are represented in differential states of segregation-integration. We controlled the inter-subject variability of illusory/cross-modal perception parametrically, by introducing temporal lags in the incongruent auditory-visual articulations of speech sounds within the McGurk paradigm. The states of segregation-integration balance were captured using two alternative computational approaches. First, the module responsible for cross-modal binding of sensory signals defined as the perceptual binding network (PBN) was identified using standardized parametric statistical approaches and their temporal correlations with all other brain areas were computed. With increasing illusory perception, the majority of the nodes of PBN showed decreased cooperation with the rest of the brain, reflecting states of high segregation but reduced global integration. Second, using graph theoretic measures, the altered patterns of segregation-integration were cross-validated.
Parents have reported emotional regulation problems in cognitive disengagement syndrome (CDS) and attention deficit and hyperactivity disorder (ADHD). The first objective of this research was to explore the differences between the parents' ratings on CDS, ADHD, hyperactivity/impulsivity, inattention, anxiety, depression and emotional dysregulation. The second one was to compare the predictive capacity of CDS and ADHD over anxiety, depression and emotional regulation problems. The third one was to analyze the mediation of emotional dysregulation in CDS, ADHD, hyperactivity/impulsivity, inattention, and anxiety and depression. The sampling used was non-probabilistic. The final sample consisted of 1,070 participants (484 fathers and 586 mothers) who completed the Emotion Regulation Checklist (ERC) and the Child and Adolescent Behavior Inventory (CABI). In relation to the first objective, first, mothers reported more emotional regulation problems in children than in fathers. Second, emotional regulation problems were more strongly correlated with hyperactivity/impulsivity. Significant differences were found in all father scores, except for anxiety and the emotional regulation subscale. Regarding mothers, significant differences were only observed in ADHD scores, hyperactivity/impulsivity, and depression. Both parents reported more problems in older children, except for hyperactivity/impulsivity scores and ADHD rated by mothers. According to the second objective, CDS scores were found to significantly predict anxiety and depression scores, but not those of inattention or emotional regulation problems. Finally, in relation to the third objective, emotional regulation problems mediated the relationships between CDS, ADHD, and anxiety and depression. In conclusion, the data support the importance of emotional regulation problems in understanding CDS and its relationship with ADHD, anxiety, and depression.
The diagnosis of cervical lymph node metastasis from thyroid cancer is an essential stage in the progression of thyroid cancer. The metastasis of cervical lymph nodes directly affects the prognosis and survival rate of patients. Therefore, timely and early diagnosis is crucial for effective treatment and can significantly improve patients' survival rate and quality of life. Traditional diagnostic methods, such as ultrasonography and radionuclide scanning, have limitations, such as complex operations and high missed diagnosis rates. Raman spectroscopy and FTIR spectroscopy can well reflect the molecular information of samples, have characteristics such as sensitivity and specificity, and are simple to operate. They have been widely used in clinical research in recent years. With the development of intelligent medical diagnosis technology, medical data shows a multi-modal trend. Compared with single-modal data, multi-modal data fusion can achieve complementary information, provide more comprehensive and valuable diagnostic information, significantly enhance the richness of data features, and improve the modeling effect of the model, helping to achieve better results. Accurate disease diagnosis. Existing research mostly uses cascade processing, ignoring the important correlations between multi-modal data, and at the same time not making full use of the intra-modal relationships that are also beneficial to prediction. We developed a new multi-modal separation cross-fusion network (MSCNet) based on deep learning technology. This network fully captures the complementary information between and within modalities through the feature separation module and feature cross-fusion module and effectively integrates Raman spectrum and FTIR spectrum data to diagnose thyroid cancer cervical lymph node metastasis accurately. The test results on the serum vibrational spectrum data set of 99 cases of cervical lymph node metastasis showed that the accuracy and AUC of a single Raman spectrum reached 63.63% and 63.78% respectively, and the accuracy and AUC of a single FTIR spectrum reached 95.84% respectively and 96%. The accuracy and AUC of Raman spectroscopy combined with FTIR spectroscopy reached 97.95% and 98% respectively, which is better than existing diagnostic technology. The omics correlation verification obtained correlation pairs of 5 Raman frequency shifts and 84 infrared spectral bands. This study provides new ideas and methods for the early diagnosis of cervical lymph node metastasis of thyroid cancer.
1,197,035. Aqueous aminoplast composition. L'OREAL. 19 April, 1967 [19 April, 1966], No. 49300/69. Heading C3R. [Also in Division D1] An aqueous composition used in the treatment of hair comprises at least one compound of the formula in which R is a hydrogen atom or alkyl radical and a perfume and optionally an acid catalyst, e.g. acetic, lactic, citric, phosphoric or sulphuric acid or an acid phosphate. The composition which may contain 0À2-10% by weight of the active compound may be an aqueous alcoholic solution or may be in the form of a cream, gel, emulsion or aerosol foam, and may also contain other adjuvants used in cosmetics, e.g. dyes, surface-active agents or swelling agents such as paraffin oil and the reaction product of 1 mole of oleyl alcohol with 10 moles of ethylene oxide.
The invention relates to a traditional Chinese medicine orally and externally taken for treating abdominal external hernia, and in particular relates to an orally taken traditional Chinese medicinal powder and an externally applied preparation for treating abdominal external hernia without incarceration and strangulation and a preparation method thereof. The traditional Chinese medicine is characterized by comprising 49 litchi seeds, 20g of lindera aggregate powder, 20g of pericarpium citri reticulatae viride powder, 20g of szechwan Chinaberry fruit powder, 20g of fennel powder, 20g of tangerine seed powder, 20g of fructus evodiae powder, 20g of cinnamon powder, 20g of moutan bark powder, 20g of divaricate saposhnikovia root powder and 45g of hawthorn pulp powder. The preparation method comprises the following steps: frying funnel and buckwheat flour, putting one semen momordicae and one rhizoma typhonii, grinding and regulating amur cork tree and cottonrose hibiscus with vinegar, and packaging the medicinal materials into two bags which are alternately pressed on and warm the affected part. The medicine can be used for treating abdominal external hernia of people, particularly old people and children, can reduce pain and is remarkable in treatment effect. The powder and an application preparation for treating abdominal external hernia without incarceration and strangulation has the beneficial effects that the patient does not need to be hospitalized or have an operation or an injection, no pains or toxic or side effects are caused, the use method is simple, safe and reliable, the disease condition can be effectively relieved under conditions that normal work, normal life of a patient are not influenced, and the patient is in an easy mind until going well. The medicine is economical and practical, convenient to operate, easy to take, low in raw material cost, easy and practical, and can reduce the economical burden and psychical stimulation of the patient.
The present invention relates to a cervical vertebra medicinal magnetic therapeutical pillow which is characterized in that a traditional Chinese medicine pad is arranged on the upper surface of a pillow body, and magnetic materials and infrared generating materials are arranged in the pillow body. The surface of the pillow body is in the shape of a curve which dovetails with the physiological curvature of the neck part of a human body. The peak of the pillow body dovetails with the seventh cervical vertebra part of the human body. The height of the peak of the pillow body is selected to be from 4cm to 6cm, preferably from 5 to 5.5cm. The length of the bottom of the pillow body is from 22cm to 25cm, and the width of the bottom is from 12cm to 14cm. The pillow surface radian of the cervical vertebra medicinal magnetic therapeutical pillow accords with the physiological curvature of the neck part of the human body. The present invention is matched with traditional Chinese medicine, infrared rays and high-tech biologic magnetism, adopts the multiple effects and the treating function of nanotechnologies and has the advantages of good cervical vertebra treatment effect and easy use.
Linear ultrasound probe and the sacral hiatus at the sacral cornu level was visualized using an out-of-plane transverse view at 5-10 megahertz . The linear probe was then rotated 90 degrees and placed longitudinally in the midline to evaluate the sacral cornus, sacrococcygeal ligament and sacral bone.
Sole ulcers, a common cause of lameness is the costliest non-infectious foot lesion in dairy cows and one of the most prevalent non-infectious foot lesions in freestall housing systems. Costs associated with sole ulcers are treatment costs, plus increased labor and decreased productivity and fertility. Routine hoof trimming is part of a strategy to manage sole ulcers. However, hoof trimming strategies differ among farms. The two most frequently applied strategies are: 1) partial herd hoof trimming with a 2-month interval between trims; and 2) whole herd hoof trimming at 6-month intervals. A Markov model was developed to investigate whether every 2 months partial herd hoof trimming or whole herd hoof trimming every 6 months was the most cost-effective strategy to avoid costs associated with sole ulcers. In this model, the net benefits for a 100-cow herd and the average productive life span of a dairy cow in intensive dairy systems of 3 years were evaluated. Partial herd hoof trimming was the most cost-effective strategy 100% of the time compared to whole herd hoof trimming, with a difference in 3-year net benefits of US$4,337 (95% CI: US$2,713-US$5,830). Based on sensitivity analyses, variables that were the sources of the biggest uncertainty in the model were herd size, the probability of being trimmed in a partial herd trim, and the prevalence of sole ulcers. To further investigate the impacts of herd size and of probability of being trimmed, various scenario analyses were conducted. With increasing herd size, the difference in net benefits in favor of partial herd hoof trimming increased even more. Scenario analyses about the probability of getting trimmed all indicated that targeted intervention increased the difference in net benefits in favor of partial herd hoof trimming. However, if the selection of cows to be trimmed in a partial herd trim was random, the whole herd hoof trimming strategy became cost-effective. Therefore, targeted selection and early intervention are necessary to decrease costs associated with sole ulcers.
FIELD: veterinary microbiology. SUBSTANCE: method involves the use of strain Chlamidia psittaci ВГИКИ "B-75" N 18 showing stable immunogenic properties, insignificant reactivity and high cytopathic action on the culture ФЭК which can be used for preparing inactivated cultural antichlamydiosis vaccine for cattle. Triple vaccination with inactivated vaccine of the strain Chlamidia psittaci ВГИКИ N 18 to heifers provides expressed immunity in newborn calves. Living mass of vaccinated calves is increased by 10% while 33% of nonvaccinated calves are sick. Vaccine shows prophylaxis postnatal complications in vaccinated animals. EFFECT: enhanced effectiveness of strain proposed. 2 tbl
PCT No. PCT/US96/17183 Sec. 371 Date Aug. 20, 1998 Sec. 102(e) Date Aug. 20, 1998 PCT Filed Oct. 24, 1996 PCT Pub. No. WO97/15301 PCT Pub. Date May 1, 1997A method of adjusting the circadian rhythm of a mammal comprising administering to said an effective circadian rhythm adjusting amount of 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamide or a pharmaceutically acceptable salt thereof is disclosed. The method of the invention may be useful to assist shift workers adjust to rotating work schedules, to alleviate the effects of jet-lag on travelers to remote time zones and/or to treat sufferers of delayed sleep phase syndrome.